SEC Form 4 · accession 0001225208-19-003457
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert W.A. Sellers
Officer — VP, Corporate Controller
Period of report
Feb 22, 2019
Accepted (ET)
Feb 22, 2019 · 7:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 22, 2019 | M | 500 | $35.785 | A | 13,782 | D | |
| Common StockF1 | Feb 22, 2019 | S | 500 | $175.0387 | D | 13,282 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire) | $35.785 | Feb 22, 2019 | M | 500 | D | May 14, 2014 | May 13, 2020 | Common Stock | 500 | 7,297 | D |
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $175.03 to $175.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Remarks
This Form 4 reflects changes in beneficial ownership only, it does not identify other securities of the Issuer beneficially owned by the Reporting Person.